Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 20/20 | 0.81 |
| ▸ | DPP8 | Q6V1X1 | 14/20 | 0.81 |
| ▸ | DPP7 | Q9UHL4 | 14/20 | 0.81 |
| ▸ | FAP | Q12884 | 1/20 | 0.81 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.81 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gosogliptin SCHEMBL197108 | 0.90 | DPP4 (1.00) | DPP4DPP8DPP7FAPDPP9 | |
| Gosogliptin SCHEMBL23715004 | 0.90 | DPP4 (1.00) | DPP4DPP8DPP7FAPDPP9 | |
| SCHEMBL3848283 | 0.86 | DPP4 (1.00) | DPP4DPP8DPP7FAPDPP9 | |
| Hydrochloric Acid SCHEMBL3841149 | 0.85 | DPP4 (0.98) | DPP4DPP8DPP7FAPDPP9 | |
| Hydrochloric Acid SCHEMBL3841151 | 0.85 | DPP4 (0.98) | DPP4DPP8DPP7FAPDPP9 | |
| SCHEMBL3843211 | 0.82 | DPP4 (1.00) | DPP4DPP8DPP7FAPDPP9 | |
| SCHEMBL3842509 | 0.82 | DPP4 (1.00) | DPP4DPP8DPP7FAPDPP9 | |
| SCHEMBL3842850 | 0.81 | DPP4 (1.00) | DPP4DPP8DPP7FAPDPP9 | |
| SCHEMBL3843529 | 0.81 | DPP4 (1.00) | DPP4DPP8DPP7FAPDPP9 | |
| SCHEMBL3840953 | 0.81 | DPP4 (1.00) | DPP4DPP8DPP7FAPDPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140066369-A1 | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto | ARENA PHARMACEUTICALS, INC. (US) | 2014-03-06 | — | — | US | disclosed |
| US-20140051629-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2014-02-20 | — | — | US | disclosed |
| US-20140051714-A1 | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto | ARENA PHARMACEUTICALS, INC. (US) | 2014-02-20 | — | — | US | disclosed |
| US-20140038889-A1 | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto | ARENA PHARMACEUTICALS, INC. (US) | 2014-02-06 | — | — | US | disclosed |
| US-20140018371-A1 | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto | ARENA PHARMACEUTICALS, INC. (US) | 2014-01-16 | — | — | US | disclosed |
| US-20130023494-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2013-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140038889-A1 | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto | GPR119, GLP1R, DPP4 | DPP4 3/4885DPP8 15/4885DPP7 9/4885 |
| US-20130023494-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | GPR119, SLC5A2, SLC5A1 | DPP4 10/4885DPP8 41/4885DPP7 18/4885 |
| US-20140051629-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | GPR119, GLP1R, DPP4 | DPP4 3/4885DPP8 10/4885DPP7 8/4885 |
| US-20140051714-A1 | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto | GPR119, GLP1R, DPP4 | DPP4 3/4885DPP8 11/4885DPP7 9/4885 |
| US-20140066369-A1 | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto | GPR119, GLP1R, SLC5A2 | DPP4 6/4885DPP8 28/4885DPP7 11/4885 |
| US-20140018371-A1 | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto | GPR119, GCGR, GLP1R | DPP4 9/4885DPP8 48/4885DPP7 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.